Tenaya Therapeutics Q3 net loss narrows 7% to $18.94 million

Bitget2026/11/04 21:18

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Tenaya Therapeutics’ third-quarter 2026 net loss narrowed 7% year-over-year to $18.94 million; collaboration revenue reached $1.7 million.
Cash and cash equivalents totaled $66.8 million at September 30, sufficient to fund planned operations into the fourth quarter of 2027.
TN-401 received FDA Regenerative Medicine Advanced Therapy designation in September for PKP2-associated arrhythmogenic right ventricular cardiomyopathy.
Updates covering TN-201 and TN-401 clinical data and regulatory feedback for pivotal trial planning are expected by year-end.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tenaya Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611041605PRIMZONEFULLFEED9870529) on November 04, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Tenaya Therapeutics Q3 net loss narrows 7% to $18.94 million

You may also like

Crypto prices